Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Trastuzumab Herceptin

Trastuzumab (Herceptin ) Roche mAb HER-2 HER-2 overexpressing breast cancer in the adjuvant and metastatic settings... [Pg.1193]

Trastuzumab (Herceptin) Humanized antibody, IgGi ErbB2/Her-2 Receptor down-regulation Breast cancer... [Pg.1255]

Standardization of IHC/ICC has been a critical issue for more than three decades, especially with the advances in targeted therapy such as the development of trastuzumab (Herceptin) for advanced breast cancer.51 Nevertheless, standardization is a difficult issue because numerous factors may influence the consistency and reliability of immunostaining results, including fixatives, fixation time, AR, antibody clones, detection system, and interpretation (see Part II). In cytopathology, the situation is even worse due to its variable cell sample preparation techniques. Cytopreparation is. .. the foundation of cytomorphology. 52 We believe it is also the foundation of ICC. Therefore, standardization of ICC needs to start with uniform and reliable cytopreparation. [Pg.228]

Trastuzumab (Herceptin) -humanized mouse monoclonal antibody directed against HER-2/new receptor -fevers, chills, nausea, vomiting, headache during administration -cardiotoxicity (the FDA has not approved concurrent use with doxorubicin)... [Pg.180]

Chiu SJ, Ueno NT, Lee RJ (2004) Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J Control Release 97 357-369... [Pg.24]

Trastuzumab Herceptin Humanized IgGltc anti-HER2 HER2 overexpressing metastatic breast cancer 1998 United States... [Pg.114]

Trastuzumab Herceptin Genentech-Roche Metastatic breast cancer... [Pg.225]

Baselga, J., D. Tripathy, J. Mendelsohn, S. Baughman, C. C. Benz, L. Dantis, N. T. Sklarin, A. D. Seidman, C. A. Hudis, J. Moore, P. P. Rosen, T. Twaddell, I. C. Henderson, and L. Norton. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 26 78-83.1999. [Pg.126]

Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of Trastuzumab (Herceptin). Semin Oncol 1999 26(Suppl 12) 60-70. [Pg.346]

Trastuzumab (Herceptin) [Antineeplastic/Monoover express the HERlIneu. protein breast CA adjuvant, w/ doxorubicin, cyclophosphamide, and paclitaxel if pt HER2/neu(+) Action MoAb binds human EGF receptor 2 protein HER2) mediates cellular cytotox Dose Per protocol, typical 2 mg/kg/IV/wk Caution [B, ] CV dysfxn, alla-gy/inf Rxns Contra Live vaccines Disp Inj SE Anemia, cardiomyopathy, nephrotic synd, pneumonitis Interactions t Risk of cardiac dysfxn W/ anthracycline, cyclophosphamide, doxorubicin, epirubicin EMS Cardiomyopathy, ventricular dysfxn and pulm tox have been reported monitor for Sxs of reduced cardiac Fxn OD Sxs unknown... [Pg.310]

While no biopharmaceutical is approved with the requirement of genotyping as a part of its therapeutic indication, a recently approved monoclonal antibody therapy against breast cancer, trastuzumab (Herceptin), is indicated only for those tumors measurably expressing the protein expressed by the gene erbB-2. Because the oncogene product of erbB-2 is elevated... [Pg.397]

Note Thalidomide is labeled for use only in erythema nodosum leprosum in the USA Trastuzumab (Herceptin)... [Pg.1208]

See other pages where Trastuzumab Herceptin is mentioned: [Pg.590]    [Pg.15]    [Pg.220]    [Pg.40]    [Pg.129]    [Pg.248]    [Pg.349]    [Pg.54]    [Pg.9]    [Pg.341]    [Pg.328]    [Pg.341]    [Pg.397]    [Pg.556]    [Pg.318]    [Pg.66]    [Pg.34]    [Pg.37]    [Pg.117]    [Pg.48]    [Pg.95]    [Pg.119]    [Pg.88]    [Pg.53]    [Pg.248]    [Pg.275]    [Pg.400]    [Pg.396]    [Pg.418]    [Pg.6]   
See also in sourсe #XX -- [ Pg.272 , Pg.1569 ]



SEARCH



Herceptin

© 2024 chempedia.info